13F filer · CIK 1791827
Avidity Partners Management LP
DALLAS, TX · filing since Q4 2019 · last filing Aug 14, 2026
Reported value
$624.4M
$-311.3M vs prior
Positions
45
New / sold out
9 / 16
Added / reduced
4 / 27
Turnover
7.0%
buys $54.4M · sells $490.6M
Top-10 weight
81.9%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | MOBIA MED INC | +798,282 | – | +$10.7M |
| New | IMMUNIC INC | +669,941 | – | +$10.3M |
| New | SENSEONICS HLDGS INC | +1,600,000 | – | +$9.1M |
| Added | CG ONCOLOGY INC | +110,000 | +8.5% | +$7.8M |
| New | NUVECTIS PHARMA INC | +200,000 | – | +$3.7M |
| New | ALAMAR BIOSCIENCES INC | +110,000 | – | +$3.0M |
| Added | INSULET CORP | +14,000 | +140.0% | +$2.1M |
| New | AVALYN PHARMACEUTICALS INC | +60,000 | – | +$2.0M |
| New | KAILERA THERAPEUTICS INC | +80,000 | – | +$1.8M |
| Added | STRUCTURE THERAPEUTICS INC | +20,000 | +25.6% | +$1.1M |
3 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | DIANTHUS THERAPEUTICS INC | -2,104,184 | -50.0% | $-205.1M |
| Reduced | ORUKA THERAPEUTICS INC | -760,424 | -50.0% | $-72.4M |
| Reduced | JADE BIOSCIENCES INC | -1,100,708 | -39.3% | $-24.5M |
| Reduced | PERSPECTIVE THERAPEUTICS INC | -5,799,999 | -47.9% | $-19.8M |
| Reduced | TEVA PHARMACEUTICAL INDS LTD | -450,100 | -69.2% | $-15.2M |
| Reduced | AKTIS ONCOLOGY INC | -452,932 | -48.3% | $-14.6M |
| Sold out | IMMUNIC INC | -7,369,352 | -100.0% | $-13.9M |
| Reduced | ENLIVEN THERAPEUTICS INC | -250,000 | -31.3% | $-12.7M |
| Reduced | VIR BIOTECHNOLOGY INC | -1,050,000 | -66.9% | $-10.7M |
| Reduced | PALVELLA THERAPEUTICS INC NE | -70,000 | -50.0% | $-10.7M |
33 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | DIANTHUS THERAPEUTICS INCCOM | 2,104,184 | $205.1M | 32.85% |
| 2 | CG ONCOLOGY INCCOM | 1,398,948 | $99.4M | 15.92% |
| 3 | ORUKA THERAPEUTICS INCCOM | 760,424 | $72.4M | 11.59% |
| 4 | JADE BIOSCIENCES INCCOM NEW | 1,700,708 | $37.8M | 6.05% |
| 5 | ENLIVEN THERAPEUTICS INCCOM | 550,000 | $27.9M | 4.47% |
| 6 | PERSPECTIVE THERAPEUTICS INCCOM NEW | 6,299,999 | $21.5M | 3.44% |
| 7 | AKTIS ONCOLOGY INCCOM | 484,200 | $15.6M | 2.50% |
| 8 | PALVELLA THERAPEUTICS INC NECOM | 70,000 | $10.7M | 1.71% |
| 9 | MOBIA MED INCCOMMON STOCK | 798,282 | $10.7M | 1.71% |
| 10 | REPLIGEN CORPCOM | 77,800 | $10.6M | 1.70% |
35 more rows. Subscribe for $29/month to see every row, download the data and use the API.